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Abstract
In multiple sclerosis, a complex neurodegenerative disorder, a combination of genetic and
environmental factors results in inflammation and myelin damage. Recent transcription-profiling
studies have found distinct gene-expression patterns in diseased tissue; such large-scale studies at
different stages of the disease are contributing to understanding multiple sclerosis and developing
effective therapy.
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Multiple sclerosis (MS), a chronic disease of the central
nervous system (CNS), is characterized by a relapsing-remit-
ting or progressive clinical course and by the pathological
triad of inflammation, demyelination, and gliosis (scarring).
MS is one of the most common causes of neurological dis-
ability arising in early to middle adulthood and thus is a
major health problem, particularly in Western societies. A
large body of evidence supports the idea that MS is a
complex disorder resulting from an interaction between an
inherent genetic susceptibility and undefined environmental
exposures. This interaction unleashes a cascade of molecular
events that culminate in a relapsing inflammatory, and ulti-
mately progressive, neurodegenerative process [1,2].
The histopathological hallmark of MS is the demyelinating
plaque, usually a sharply circumscribed lesion in the CNS
white matter that evolves dynamically [3]. In the early
(acute) stage, lymphocytes (predominantly T cells) pass
through the walls of blood vessels and infiltrate white matter,
apparently orchestrating the demyelinating process. In some
inflammatory lesions, a distinctive pattern of myelin damage
can be seen and appears to be associated with the deposition
of myelin-specific autoantibodies. As lesions evolve over
time, inflammation lessens and astrocytes (star-shaped glial
cells that respond to injury) proliferate extensively, resulting
in a gliotic scar. Oligodendrocytes, the myelin-producing
glial cells, are either destroyed as the inflammatory and
gliotic process evolves or may proliferate and mediate partial
remyelination. Some MS plaques appear to gradually enlarge
by concentric outward growth. 
Recent ultrastructural studies of MS lesions suggest that
fundamentally different underlying pathologies may be
present in different patients. Heterogeneity has been identi-
fied both in terms of the fate (that is, death or survival) of
oligodendrocytes and by the presence or absence of deposi-
tion of antibody and complement. Rare cases may even have
a primary oligodendrogliopathy without prior inflammation.
In most MS cases, tissue damage and neurological impair-
ment reflect the downstream outcome of a coordinated
series of events that includes peripheral lymphocyte activa-
tion, disruption of the blood-brain barrier, infiltration of
inflammatory cells into the brain parenchyma, further stim-
ulation of myelin-reactive T cells in the nervous system,
autoantibody deposition, demyelination, and axonal loss.
Cytokines, adhesion molecules, growth factors, and other
molecules such as free radicals, proteases and vasoactive
amines are thought to induce and regulate numerous criti-
cal disease-associated cellular functions (Figure 1). The
comprehensive analysis of these cellular transcriptional
programs - the transcriptome - both in the CNS and the
periphery may identify one or several distinct molecular fin-
gerprints and may contribute to a more accurate model of
MS pathogenesis. 
The Human Genome Project has facilitated large-scale high-
throughput analysis of differential gene expression, allowing
progress in functional interpretation of genomic information
[4-7]. Of these methods, DNA microarrays and quantitative
real-time PCR have been the most utilized. Whichever type
of microarray is used for hybridization with a labeled cRNA
or cDNA population from the sample(s) of interest, sophisti-
cated detection systems can then read and quantitate the
amount of each specific mRNA present in the original
sample(s) (see Figure 2). A structured classification of genes
or experiments according to temporal and/or topographic
transcriptional patterns can thus be obtained, most com-
monly by using hierarchical clustering [8]. The differential
expression of a manageable number of targets can be vali-
dated by sensitive real-time PCR, and these can be further
assessed using in vivo models. 
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Figure 1
A model of MS pathogenesis. T cells become activated in the periphery by processed peptides expressed by antigen-presenting cells in the context of
MHC molecules (see inset). In MS, these peptides are thought to mimic the molecular shape of some CNS antigens. Activated T cells undergo
transcriptional changes resulting in the expression of adhesion molecules and proteolytic enzymes that favor their adhesion to the basal lamina of the
capillary vessels of the blood-brain barrier. The T cells then pass out of the blood vessels (extravasation) to the brain parenchyma where they are
reactivated by astrocytes or microglial cells now presenting CNS antigens. This second activation step triggers a new wave of inflammation in which
numerous cytokines, chemokines, and other molecules such as NO, glutamate, and free radicals are produced. This process is maintained by positive
feedback loops acting on effector cells, and eventually results in damage to myelin, oligodendrocytes, and neurons. 
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Figure 2 
Functional genomics of MS. (a) Accurate diagnosis of patients based on clinical evidence, particularly magnetic resonance imaging, and the patients’
historical data, is pivotal for the validity of genomic analysis. (b) Typically, post-mortem samples with short autolysis times are used, although biopsy
specimens are sometimes available. Immunohistological analysis and laser capture microdissection at this stage can add substantially to subsequent data
interpretation. (c) High-quality RNA is then obtained from the tissue and subjected to quantitation and integrity analysis. (d) Depending on the type of
array to be used, the RNA sample is converted into fluorophore-labeled cDNA (spotted cDNA arrays) or cRNA (oligonucleotide-based arrays). (e) A
nucleic-acid-containing solid support - the DNA chip or microarray - is obtained either by spotting cDNA clones or by in situ synthesis of
oligonucleotides onto a glass surface. (f) The labeled sample is then laid on top of the array and hybridized for several hours. In the case of spotted
cDNA arrays, an equal amount of two differently labeled samples (usually one is a control) is mixed prior to the hybridization step. (g) A confocal laser
microscope can be used to scan and measure the fluorescence emitted by the hybridized probes. The intensity of the signal is directly related to the
amount of mRNA originally present in that sample. In spotted cDNA arrays, the ratio of the two fluorophores is measured and the relative intensity of
each probe is then calculated for each cDNA-containing spot. (h) Different classification algorithms can be used to organize the expression of all genes
analyzed in a particular experiment. In this way, genes with correlated patterns of expression are clustered together and so can be readily identified. (i)
On the basis of the expression results, a particular gene or group of genes can be selected for validation in vivo. At this stage, animal models can be used
to assess the effect of a genetic deletion or overexpression affecting the gene(s) of interest. (j) At the end of this process, a hypothesis can be generated
that is consistent with the results obtained. New rounds of experimentation are usually required to refine a particular hypothesis.
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Large-scale gene-expression studies in MS 
An early example of large-scale expression profiling of the
MS lesion was provided by Becker et al. [9], who constructed
and sequenced a normalized cDNA library from a brain
sample obtained post-mortem from a patient with the
primary progressive form of the disease. This study, albeit
not statistically powerful, identified several inflammatory
genes and known putative autoantigens that were present in
the MS-derived libraries but absent from two normal control
libraries. In a subsequent report by the same group [10],
spotted cDNA microarrays were used to interrogate the
expression levels of more than 5,000 genes in the same spec-
imen. In this study the authors describe the differential
expression of 62 genes, including those encoding the Duffy
chemokine receptor, interferon regulatory factor-2, and
tumor necrosis factor . The absence of total or even partial
replication between the screens is noteworthy. This observa-
tion highlights the large variability that is usually found in
large-scale gene-expression profiling experiments when dif-
ferent experimental platforms are employed. 
One of us (S.E.B.) recently reported the high-throughput
sequencing of diseased brain-expressed transcripts using
cDNA non-normalized libraries generated from MS lesions
and control brain [11]. Over 11,000 clones were sequenced,
and analysis focused on genes present in MS libraries but
absent from the control library. The most abundant tran-
scripts unique to MS plaques were those for  B-crystallin,
an inducible heat-shock protein that is localized in the
myelin sheath and targeted by T cells in MS [12]. The
next five most abundant transcripts were those for
prostaglandin D synthase, prostatic binding protein, ribo-
somal protein L17, and osteopontin (OPN), also called early
T-cell activation gene-1, which has pleiotropic functions,
including roles in tissue remodeling, cell survival and cellu-
lar immunity [13,14]. OPN was also found in lesions of
experimental allergic encephalomyelitis (EAE), a murine
model with similarities to MS. In addition, OPN expression
in neurons was detectable during acute disease and relapse,
but not during remission. OPN-deficient mice were resis-
tant to progressive EAE and had frequent remissions.
Responses mediated by type 1 T-helper cells involved in
CNS autoimmunity may be regulated by OPN, making it a
possible target for new therapies.
Ramanathan et al. [15] reported the analysis of brain
samples from 15 relapsing-remitting MS patients and 15
controls by probing nylon cDNA arrays. Only 34 out of
4,000 genes interrogated showed statistically significant dif-
ferential expression in MS samples when compared to con-
trols. Surprisingly, only a very small fraction of these genes
can be directly associated with current models of MS patho-
genesis or with its downstream inflammatory effects. Bona
fide regulatory changes in gene expression may have been
obscured in this study by the low signal-to-noise ratio char-
acteristic of molecular control processes.
In the most recent report on the application of microarrays to
MS, Lock et al. [16] described the analysis of four dissected
brain specimens from chronic or secondary progressive MS
patients and compared them with two specimens from non-
inflammatory post-mortem brain tissue. The dissected
lesions ranged from acute inflammatory to chronic silent,
spanning a broad range of plaque activity. Lock et al. [16]
found a set of 49 genes that showed increased expression and
39 genes with decreased expression in all four MS samples
compared with the two control brain specimens. Among the
overexpressed transcripts, HLA (MHC) class II and
immunoglobulin genes were of particular interest, because
they reflect an active immune response in the lesions. Also
noteworthy was the higher expression of immunoglobulin
genes in acute plaques than in chronic silent lesions. Simi-
larly, granulocyte colony-stimulating factor (G-CSF) was
upregulated for most of the active plaque types. This finding
was validated in vivo using the EAE model: animals that pre-
viously received a subcutaneous dose of G-CSF developed a
much milder disease than control animals, suggesting an
active immunomodulatory mechanism upregulating the pro-
duction of this trophic factor in EAE and MS lesions. Another
gene differentially upregulated according to the type of lesion
was the immunoglobulin Fc receptor  subunit (FcR), which
showed a significantly higher expression in the chronic silent
than the acute plaques. Transgenic mice with a reduced
expression of the FcR gene also showed a milder clinical
course of EAE than did their normal littermates. Genes with
decreased expression included those for several myelin com-
ponents, such as proteolipid protein, myelin-associated gly-
coprotein, and myelin oligodendrocyte glycoprotein. This last
finding may reflect not only the catabolic demyelinating
process but also ineffective or absent myelin repair. Overall,
this impressive study illustrates the validity of the functional
genomics approach as a hypothesis generator. 
The need for standards and crossvalidation
Studies such as those described here [9-11,15,16] can provide
valuable information about the molecular mechanisms
underlying plaque formation, but their interpretation is
subject to a number of issues. Firstly, discrepancies observed
between studies could be related to the use of different plat-
forms for assessing the expression profiles, so rigorous
crossvalidation is required before accurate comparisons can
be performed. The different mechanisms of plaque forma-
tion present in different subsets of patients, or comparison
of samples obtained at different time points in the evolution
of the plaque, could lead to discrepancies.
A second issue in interpreting the recent studies is that in
most large-scale gene-profiling studies only a small fraction
of the expected candidate genes appear as differentially reg-
ulated. For example, genes involved in T-cell and proinflam-
matory functions would be expected to be abundantly
expressed in an MS lesion. Controls - both normal and other
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neurological disease controls - should be carefully selected in
order to maximize the chance that disease-specific changes
will be revealed. Similarly, differences in the effective con-
centration and stability of each mRNA species can be mini-
mized by meticulous selection and systematic processing of
fresh specimens.
A third issue is that the high costs involved mean that often a
very few samples are analyzed, compromising the statistical
significance of the experiments, and (equally important)
only representing a momentary snapshot of the dynamic
process they are meant to depict. 
The importance of longitudinal analyses in
dynamic disease states
Most gene-expression profiling reports on the MS plaque
have involved single, descriptive experiments that capture
only the physiological and molecular stages at which the
sample under study was harvested. Given the dynamic nature
of the inflammatory and degenerative processes that operate
in MS, longitudinal studies using animal models may provide
a context for the interpretation of snapshots derived from the
limited human histopathological material available to investi-
gators - material which by necessity reflects a sampling bias
created by the clinical situations that resulted in availability
of biopsy or autopsy tissue for examination. 
In addition to different variants of MS, the clinical course in
an individual person is characterized by abrupt or gradual
perturbations in disease activity. The hallmark of dynamic
disease states is the sudden, qualitative and quantitative
change in the temporal pattern of physiological events that
underlie the disease. Longitudinal monitoring of plaque
activity or other biological compartments by expression
analysis may allow the identification of temporal patterns
and underlying cellular events that drive tissue damage in
MS. In other dynamic diseases, recognition of these patterns
already forms a basis for therapeutic decision-making [17].
In conclusion, large-scale gene-expression profiling methods
have already provided an initial burst of information about
MS to complement the histopathological and imaging data
accumulated to date. The combined analysis of the genomic
and transcriptional information, together with the modeling
of genetic networks, may help to predict the responses of a
particular biochemical pathway under a variety of different
stimuli, simulated feedback loops, or other interactions. A
useful conceptual model of the inflammatory events that
drive demyelination and neurodegeneration in MS may
emerge that can provide understanding of existing therapies
as well as a rationale for novel treatment strategies.
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